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Abstract
The cohesin complex is crucial for chromosome segregation during mitosis and has recently also been implicated in
transcriptional regulation and chromatin architecture. The NIPBL protein is required for the loading of cohesin onto
chromatin, but how and where cohesin is loaded in vertebrate cells is unclear. Heterozygous mutations of NIPBL were found
in 50% of the cases of Cornelia de Lange Syndrome (CdLS), a human developmental syndrome with a complex phenotype.
However, no defects in the mitotic function of cohesin have been observed so far and the links between NIPBL mutations
and the observed developmental defects are unclear. We show that NIPBL binds to chromatin in somatic cells with a
different timing than cohesin. Further, we observe that high-affinity NIPBL binding sites localize to different regions than
cohesin and almost exclusively to the promoters of active genes. NIPBL or cohesin knockdown reduce transcription of these
genes differently, suggesting a cohesin-independent role of NIPBL for transcription. Motif analysis and comparison to
published data show that NIPBL co-localizes with a specific set of other transcription factors. In cells derived from CdLS
patients NIPBL binding levels are reduced and several of the NIPBL-bound genes have previously been observed to be mis-
expressed in CdLS. In summary, our observations indicate that NIPBL mutations might cause developmental defects in
different ways. First, defects of NIPBL might lead to cohesin-loading defects and thereby alter gene expression and second,
NIPBL deficiency might affect genes directly via its role at the respective promoters.
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Introduction
Genomes need to be stably inherited over numerous cell
generations. For each cell division the genetic information has to
be replicated, the copies identified and then equally distributed
between daughter cells. This process crucially depends on the
cohesin complex, consisting of the core subunits SMC3, SMC1A,
RAD21, SA1/STAG1 or SA2/STAG2 and several transiently
associated regulatory proteins (reviewed in [1]). Cohesin tethers two
sister chromatids together from S-phase on, allowing for their
proper segregation in mitosis. Furthermore, cohesin is important for
DNA damage repair (for review see [2]), for chromatin insulation in
cooperation with the chromatin insulator protein CCCTC-binding
factor (CTCF) [3–5], for chromosomal long-range interactions [6–
8], and for development [9–12]. The latter functions implicate
cohesin in regulating gene expression; indeed, a large number of
genes are misregulated after cohesin depletion [3,13].
How exactly cohesin associates with DNA is not understood,
since none of the subunits binds directly to DNA. Rather, cohesin
is hypothesized to bind to DNA by embracing the DNA strands
with a ‘‘protein ring’’ formed by the core subunits [14,15].
Cohesin’s binding to chromatin is tightly regulated throughout
the cell cycle. To enable chromosome segregation it is removed
from chromosomes during mitosis. A prophase pathway depend-
ing on WAPL and specific phosphorylation of cohesin subunits
dissociates cohesin from chromosome arms. The remaining
cohesin is removed by proteolytic cleavage of the RAD21 subunit
at anaphase onset (reviewed in [1]). Cohesin re-associates with
chromatin at the G1-S-phase transition in yeast but in vertebrates
already earlier during G1 phase.
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The chromosomal localization of cohesin is determined by
several factors. First, the cohesin loading factors NIPBL (also
known as IDN3 or Delangin; Nipped-B, Drosophila melanogaster;
Scc2, Saccharomyces cerevisiae) and MAU2 (also KIAA0892; Scc4 in
Saccharomyces cerevisiae) are crucial for the re-loading of cohesin in
G1-phase after its complete dissociation from chromatin during
mitosis (reviewed in [1]). In yeast, it has been shown that cohesin
associates first with Scc2 binding sites and then relocalizes to
different positions [16,17]. In Drosophila melanogaster cohesin
colocalizes with NIPBL to actively transcribed genes [18] and in
mouse ES cells a subset of cohesin binding sites was described to
colocalize with NIPBL and the mediator complex [13]. Second,
factors co-localizing with cohesin on chromatin such as CTCF [3]
and Estrogen receptor [19] determine where cohesin is positioned.
Mutations in NIPBL and cohesin subunits, have been linked to
the ‘‘Cohesinopathy’’ Cornelia de Lange syndrome (CdLS,
OMIM #122470, #300590 and #610759). This dominant,
genetically heterogeneous developmental disorder has a high
degree of variability in its clinical presentation with multiple organ
systems affected. It is estimated to occur in 1:60000 to 1:45000 live
births. Characteristic features include craniofacial anomalies,
growth retardation, intellectual disability, upper limb defects,
hirsutism, and involvement of the gastrointestinal and other
visceral organ systems [16]. Clinically, CdLS phenotypes can
range from very mildly affected (no structural abnormalities,
minor intellectual disability) to severely affected (upper limb
defects, severe intellectual disability). Heterozygous mutations of
NIPBL, ranging from nonsense and frameshift mutations to
truncation mutations, have been found in 50% of CdLS patients
and mutations of the cohesin subunits SMC1A, and SMC3 were
found in another 5% (reviewed in [17]). Observations in patients
and mouse models show that in cells with heterozygous NIPBL
mutations the NIPBL transcript levels are only reduced by ,30%
due to an increased expression from the intact allele [18,19]. A
clinical phenotype is observed with a modest 15% reduction in
expression [20]. This indicates that NIPBL expression levels are
tightly regulated and are critical for cells. Defects in cohesin-
dependent chromosome cohesion were not observed at this level of
NIPBL reduction in CdLS patients or any model systems [19,21].
However, a reduction of cohesin binding sites was observed in cells
derived from CdLS patients, which was most obvious in close
proximity to genes [18]. This suggested that the clinical features of
CdLS are the collective outcomes of changes in the expression
level of multiple genes during development.
NIPBL has already been linked to gene regulation. In
Drosophila, NIPBL was found to facilitate the activation of the
cut and Ultrabithorax genes by remote enhancers. In the case of the
cut gene, NIPBL facilitates its long-range activation while cohesin
has an inhibitory effect on cut expression [22]. Further, human
NIPBL was already shown to bind histone deacetylases (HDAC1,
HDAC3) [23] and heterochromatin protein 1 (HP1) [24].
These observations implied a ‘‘dual role’’ for NIPBL, in loading
cohesin and in gene regulation. It is not known whether these two
functions are independent of each other, or if NIPBL mediates
gene regulation via loading of cohesin onto DNA.
In this study we have aimed to determine when and where
NIPBL binds to chromatin to determine where cohesin is initially
loaded. Furthermore we wanted to elucidate whether the position
of NIPBL binding in the genome accounts for the altered gene
expression patterns observed in CdLS patients carrying NIPBL
mutations [18].
Results
Consecutive loading of NIPBL, CTCF and cohesin
To gain insight into the cohesin loading mechanism it is crucial
to understand when cohesin interacts with these factors during the
loading process. We have therefore compared the timing of the
chromatin-localization of cohesin with that of NIPBL and CTCF.
Mitotic HeLa cells were fixed with paraformaldehyde (PFA) and
immunostained with antibodies specific for CTCF, NIPBL and the
cohesin subunits RAD21 and SA2/STAG2 (Fig. 1; Suppl. Fig.
S1B, C). Specificity of the antibodies was demonstrated by
immunostaining of siRNA-depleted cells (Suppl. Fig. S1A). It
was then determined at which stage the signals of these proteins
appeared on chromatin during the exit from mitosis (Fig. 1). These
results were also correlated with the reassembly of the nuclear
envelope in HeLa cells expressing Lamin B-EGFP. Similar to
cohesin we find the signals of NIPBL and CTCF to be largely
excluded from metaphase chromosomes. However to our surprise
both NIPBL and CTCF signals appear on chromatin at an earlier
stage of the mitotic exit than cohesin (Fig. 1), actually before the
nuclear envelope is reassembled as shown by comparison to Lamin
B signals (Suppl. Fig. S1B). Therefore NIPBL and CTCF are
already present on chromatin, before the cohesin complex begins
to re-associate with chromatin. This suggests that NIPBL binds
first to chromatin and subsequently recruits cohesin. The fact that
CTCF associates with chromatin before cohesin enforces our
earlier observation that cohesin is dispensable for CTCF
localization on chromatin [3].
NIPBL localizes in somatic cells independently of cohesin
To analyze the genomic localization of NIPBL binding sites
relative to cohesin and CTCF, we selected the NIPBL antibody
(referred to as NIPBL#1) that performs best in human cells
(Suppl. Fig. S2) and performed ChIP-sequencing for NIPBL,
cohesin and CTCF using HB2 cells (1-7HB2) [25] enriched in G1
phase (Suppl. Fig. S3A) and for NIPBL in lymphoblastoid cells
(LCL; B-cell population immortalised by EBV-transformation)
derived from a normal control (N5) and CdLS patients (PT1,
PT9).
Furthermore, we have determined the transcriptional activity by
RNA-sequencing, and identified active transcription start sites in
Author Summary
The cohesin complex is crucial for chromosome segrega-
tion during cell divisions but was recently also implicated
in transcriptional regulation and chromatin architecture.
Cohesin’s binding to chromatin depends on NIPBL, a factor
that was found to be mutated in 50% of the cases of the
human developmental disorder Cornelia de Lange Syn-
drome (CdLS). To understand the role of NIPBL for cohesin,
we need to know when and where the cohesin is loaded
onto DNA. Our experiments have identified high-affinity
NIPBL binding sites in different cells lines which do not
overlap with cohesin-binding, but colocalize with specific
transcription factors at active promoters. The activity of the
respective genes depends on NIPBL but not cohesin. This
is in contrast with other published data showing
colocalization of NIPBL and cohesin, and we reveal the
existence of different types of NIPBL binding sites that are
detected differently by the antibodies used in the different
studies. Our observations reveal a dual role for NIPBL in
cohesin loading and as potential transcription co-factor,
which yields novel insights into how NIPBL defects could
cause Cornelia de Lange Syndrome since NIPBL mutations
might directly influence developmentally important genes.
NIPBL as Novel Transcription Co-factor
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HB2 cells by ChIP-sequencing of RNA Polymerase II (RNA Pol
II). ChIP for NIPBL, SMC3, CTCF and RNA Pol II was
performed as described [3], but for SMC1A ChIP a SDS-free
protocol was used to maximize the ChIP-efficiency [26].
To prove the specificity of the identified peaks for NIPBL we
have depleted NIPBL by RNAi and observed greatly reduced
ChIP-qPCR signals for the analysed sites (Suppl. Fig. S4 A–C).
Using the criteria described in the Materials and Methods
section, we identified 1138 NIPBL sites, 35668 CTCF sites, 22572
SMC3 sites and 29441 SMC1A sites in HB2 cells and between
1600 and 2000 NIPBL sites in lymphoblastoid cells (LCL). The
data from the different LCL’s and the conclusions for CdLS are
discussed in detail in a later section.
Surprisingly, in HB2 cells the NIPBL binding sites do not
overlap with cohesin or CTCF binding sites (Fig. 2A). Heatmaps
centred on NIPBL (Fig. 2B), cohesin or CTCF binding sites
(Fig. 2C, D), show no overlap of cohesin or CTCF signals with
NIPBL sites. As expected, there was a high correlation between
cohesin and CTCF signals. The absence of overlapping NIPBL
and cohesin sites was confirmed by qPCR analysis of several
NIPBL and cohesin binding sites in SMC3 and NIPBL ChIP
experiments, where we observe only background levels of NIPBL
binding on cohesin sites and vice versa (Fig. 2E).
Cohesin binding was previously observed on centromeric
repeats and Alu elements [27–29], therefore we also analysed
sequencing reads mapping uniquely to repeat sequences (Table
S8). NIPBL ChIP highly enriches rRNA repeats (13 fold), in
particular the large (LSU, 15 fold enriched) and small subunit
(SSU, 14 fold enriched) repeat families but not at the repeat classes
described for cohesin. rRNA repeats are pseudogenes of unknown
function distributed all over the human genome [30]. In total we
observe NIPBL at 20 out of 467 known LSU/SSU regions (Hg19
assembly of the human genome) and by ChIP-qPCR with primers
specific for LSU and SSU repeats we confirmed NIPBL-binding to
four of five LSU repeat regions and one of three SSU regions
(Suppl. Fig. S5A).
The missing colocalization between NIPBL and cohesin is in
contrast with observations in mouse embryonic stem cells (mESC)
[13]. To address this we critically reviewed the ChIP-sequencing
data analysis from Kagey et al., the ChIP protocols used and the
different antibodies, NIPBL#1 from our study and NIPBL#6
used by Kagey et al.. Our review of the ChIP-seq data analysis
from Kagey et al. confirmed their general finding that cohesin and
NIPBL ChIP signals overlap, although we did not find such a
colocalization of NIPBL and cohesin in our study. Further, we
compared the different ChIP protocols by performing ChIP from
mESC using both protocols and both antibodies (Suppl. Fig. S5B,
C). We observe a better ChIP/IgG-control ratio using our
protocol, which includes a more stringent washing of the beads
(Suppl. Fig. S5C). For three NIPBL sites at promoters (Nanog, Lefty,
Oct4), identified by Kagey et al. in mESC [13], both antibodies
perform weakly but equally well, independent of the ChIP
protocol (Suppl. Fig. S5B, C). To demonstrate once more the
specificity of both antibodies for NIPBL, we have performed ChIP
with both antibodies from control mESC and mESC derived from
a Nipbl+/2 mouse embryo (Suppl. Fig. S5D) (S. Goldberg, F.
Grosveld unpublished data) and observe with both antibodies a
20–40% decreased Nipbl binding at all sites (Suppl. Fig. S5E).
This is consistent with previous reports on Nipbl+/2 mESC that
heterozygous knockout cells still have 70% of wild-type Nipbl
mRNA levels [19].
However, on the NIPBL binding sites that we find to be
conserved between human HB2 cells and mES (Tiam1, Ankhd1,
Sp1), the ChIP is strikingly better enriched for NIPBL#1 than
NIPBL#6 in both cell types (Suppl. Fig. S5B, C, F). Therefore,
different chromatin morphologies between pluripotent and differ-
entiated cells do not account for the different binding patterns.
We conclude from these results that there are two different types
of NIPBL binding sites. The NIPBL#1 antibodies highly enrich
for a set of ‘‘major sites’’ that localize at promoters and do not
overlap with cohesin. The NIPBL#6 and NIPBL#1 antibodies
both detect a set of low-enriched sites (‘‘minor sites’’, low ChIP/
seq signals) which overlap with cohesin binding sites.
NIPBL binds to active promoters, together with a distinct
set of transcription factors
NIPBL ‘‘major binding sites’’ are distributed over the entire
genome (repetitive sequences were omitted during the mapping of
the reads to the genome) but localize very specifically to the
promoter area (+/21000 bp from transcription start sites)
(Fig. 3A). We observe such localization for 912 of 1138 (80%)
Figure 1. Chromatin association of NIPBL, cohesin and CTCF
during exit from mitosis. A To address the association of cohesin,
CTCF and NIPBL with chromatin during end of mitosis HeLa cells were
fixed with PFA and stained with antibodies against CTCF (CTCF#1), the
cohesin subunit RAD21 and NIPBL (NIPBL#2). Image stacks were taken
with a confocal microscope and a Z-projection generated with Image J.
Cells in interphase and different stages of mitosis are shown, from top
to bottom: interphase, metaphase, late anaphase, telophase, completed
cytokinesis together with a metaphase. B One image slice (100 mm) of
the telophase images in (A) is shown to highlight the lack of cohesin
signal on chromatin while NIPBL and CTCF are already present.
doi:10.1371/journal.pgen.1004153.g001
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NIPBL sites in HB2 cells, while only ,10% of the cohesin and
CTCF sites localize to promoters. About 89% of NIPBL-bound
promoters are CpG island promoters (Table S4). Analysis of RNA-
sequencing data from HB2 cells revealed that .98% of these
NIPBL-bound genes are actively transcribed (Fig. 3A and Table
S3), indicating a preferential binding of NIPBL to active
promoters. Comparison with RNA Pol II binding sites showed
that NIPBL preferentially binds 100–200 nucleotides upstream of
RNA Pol II (Fig. 3B). This correlation is also visible as bimodal
distribution of the RNA Pol II signal since orientation of
transcription was not considered in this plot (Fig. 2B).
To analyse the properties of NIPBL binding sites further, we
used the NIPBL binding sites observed in the control LCL’s (N5),
since a large number of data for histone modifications and
transcription factors is available for lymphoblastoid cells like
GM12878 from earlier publications [31] and ENCODE [32].
Comparing the pattern of different histone modifications
around NIPBL sites, we observed that the sites are flanked by
histone marks linked to active promoters and enhancers
(H3K4me3, H3K27ac and H3K9ac) (Fig. 3C). However, the
H3K4me1 mark, characteristic for enhancers, does not show
enrichment (Fig. 3C). NIPBL itself apparently resides in nucleo-
some-free areas.
The missing enhancer-specific histone mark is in contrast with
observations in mouse ES cells showing a colocalization of NIPBL
with enhancers and cohesin [13]. Therefore we also compared the
NIPBL binding with the enhancer marker p300 (Fig. 3D) and the
cohesin subunit RAD21 (Fig. 3E) and again observed no
correlation.
Motif analysis of NIPBL binding sites in HB2 cells and LCL’s
using MEME [33] reveals that the motifs for the transcription
factor NFYA (subunit of the NF-Y complex) are present at 80% of
NIPBL sites and for SP1 at 50% of the sites (Fig. 3F). NF-Y binds
the CCAAT box, which correlates well with the presence of CpG
islands at promoters; also, a connection between NF-Y and SP1
has often been reported with presence of both motifs at the same
promoter. To test whether the presence of the NFYA motif is
correlated to the CpG-island promoter or a genuine property of
the NIPBL-bound promoters we analyzed NIPBL-bound CpG
island promoters versus randomly selected CpG island promoters
and observe a statistical significant preference (Fisher test, p,
0.001) of NFYA for NIPBL-bound CpG island promoters. ChIP
with anti NFYB antibodies from HeLa cells confirms binding of
the NF-Y complex to NIPBL binding sites determined above
(Fig. 3G).
To investigate whether other transcription factors colocalize
specifically with NIPBL we compared the NIPBL sites in LCL’s
with available ChIP-sequencing data for transcription factors for
GM12878 cells collected by ENCODE [32]. Specifically, we
analyzed in total 66 binding profiles and generated heat maps
covering +/2500 bp around NIPBL binding sites conserved in
lymphoblastoid cells. By visual inspection of the maps we identified
five transcription factors present on NIPBL sites: NFYA/NFYB
and SP1, which is consistent with the presence of the motif, as well
as PBX3, C-FOS and IRF3 (Fig. 3H). The heatmaps displaying
the signals of the other transcription factors on NIPBL binding
sites show a very good correlation between all five factors. When
the signals are plotted respective to NFYB sites sorted according to
peak intensity, it shows that NIPBL and several other factors
overlap only with the strongest NFY peaks (Fig. 3I).
NIPBL is important for gene activity
NIPBL-bound genes in HB2 cells were analyzed using IPA
(Ingenuity Systems, www.ingenuity.com) and found to be linked to
diverse cellular functions, such as cell cycle control, gene
expression, cell death, RNA post-translational modification and
control of cellular growth and proliferation (Table S5). Out of
1118 NIPBL-bound protein-coding genes, 122 (11%) were
classified as transcription factors by Vaquerizas et al. 2009 [34],
which is not a statistically significant enrichment compared to the
number of transcription factors in lists with randomly selected
genes, but indicates that important developmental genes might
depend on NIPBL. Examples are SP1, SP2, SP3, BBX and STAT3,
all important transcription factors for development and NIPBL
binding at their promoters could be important for their
appropriate expression.
To address whether NIPBL is important for the active
transcription of the associated genes, we selected functionally
different genes with conserved NIPBL binding at the promoter,
but no cohesin binding site close to or on the gene, and asked
whether their transcription changes in HB2 cells after knockdown
of NIPBL, MAU2 or SMC3. To avoid problems in cell division
due to impaired sister chromatid cohesion, we synchronized cells
in G2 phase during the siRNA treatment (Suppl. Fig. S3B). Out of
the seven initially selected genes, five showed statistically
significant changes after NIPBL RNAi depletion: GLCCI1, a
glucocorticoid inducible transcript; TSPAN31, encoding a trans-
membrane protein involved in signal transduction and growth-
regulation; BBX, encoding a HMG-BOX transcription factor;
ZNF695, an uncharacterized zinc-finger protein and ARTS-1/
ERAP1, an endoplasmic reticulum aminopeptidase. Transcript
levels were analyzed by RT-PCR and qPCR and normalized
against the housekeeping gene NAD. Depletion of NIPBL and also
of MAU2 leads to a statistically significant (t-test, P-values,0.05)
decrease of gene expression levels of the candidate genes (Fig. 4),
indicating that NIPBL and MAU2 dosage are important for
maintaining expression levels. The depletion of SMC3 did not
significantly reduce the expression of these transcripts, although
the expression of the known cohesin-regulated MYC gene [35] was
reduced. This indicates that the changes in expression as a result of
NIPBL depletion are not the indirect result of reduced cohesin
binding and cohesin’s role for transcription.
Insights into Cornelia de Lange Syndrome (CdLS)
Mutations in the NIPBL gene have been identified in
approximately 50% of CdLS patients. Our discovery that NIPBL
Figure 2. Binding of NIPBL, cohesin and CTCF in the human genome. A Genomic binding of NIPBL, CTCF and the cohesin subunits SMC3
and SMC1A in the breast endothelial cell line HB2 at a selected region of chromosome 19 as determined by ChIP-sequencing. The RNA Pol II binding
profile, the control ChIP and the RNA-sequencing data from these cells are also shown. B–D Heatmaps showing the ChIP signal intensity of the
indicated ChIP-sequencing experiments in a window of +/2500 bp around all NIPBL peaks (B) as well as the top 10000 CTCF (C) and SMC3 (D) peaks.
Cohesin (SMC3, SMC1A) and CTCF binding does not correlate with NIPBL binding events. RNA Pol II signals are found near NIPBL, consistent with the
localization of NIPBL at promoters. Cohesin binding events correlate well between SMC3 and SMC1a and with CTCF. Peaks are ranked by size with the
strongest peaks at the bottom of the graph. E ChIP was performed with NIPBL#1, SMC3 and control antibodies from HB2 cells and analyzed by qPCR
with primers specific for cohesin, NIPBL and a negative (AMY) sites. NIPBL ChIP signals on cohesin sites are at background level (red horizontal line).
Only the DUSP10 site is higher than the background in the SMC3 ChIP, very likely due to a CTCF/cohesin site close to the NIPBL site. All experiments
were at least performed three times and one representative example is shown.
doi:10.1371/journal.pgen.1004153.g002
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Figure 3. NIPBL binds to active promoters together with other transcription factors. A Binding of NIPBL, CTCF and cohesin (SMC3) relative
to active genes in HB2 cells. The different regions were defined as follows; upstream: 25 kbp to 21 kbp from transcription start sites; promoter:
1 kbp upstream and downstream from TSS; gene body: +1 kbp from TSS until end of the coding sequence; downstream: end of the coding sequence
- +5 kbp (See also Table S2). B Bubble plot representation of NIPBL binding around RNA Pol II peaks in HB2 cells. The x-axis denotes the position of
NIPBL respective to the closest RNA Pol II peak and the y-axis the strength of the RNA Pol II peak. Bubble size indicates the strength of the NIPBL peak.
NIPBL binds 100–250 bp around RNA Pol II peaks, preferentially upstream, which is consistent with binding to active promoters. C NIPBL binding in
the control LCL’s (N5) was compared with localization of histone modifications and CTCF in the lymphoblastoid cell line GM12878 [31]. The plot is
centred on the NIPBL peaks and the y-axis displays the signal intensity of the respective histone modification and CTCF in GM12878 cells. D Heatmap
correlating the P300 ChIP signals +/2500 bp around P300 binding sites observed in GM12878 cells with the sequencing reads obtained for the
control and for NIPBL ChIP in control (N5) and patient cells (PT9). The plot is centred on the 10000 strongest P300 peaks clustered into different
NIPBL as Novel Transcription Co-factor
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binds to active promoters prompted us to identify the major
NIPBL binding sites in lymphoblastoid cells (LCL’s) derived from
blood samples of severely affected CdLS patients with NIPBL
truncation mutations and normal controls (Fig. 5A, B).
Using the NIPBL#1 antibody we detected 1612 major NIPBL
sites in the control (N5) and 2061/2009 sites in the patient-derived
lines (PT1/PT9), with 1295 sites overlapping between N5/PT1
and 1273 sites between N5/PT9. In summary 80% of the sites in
the control N5 are also found in PT1 and PT9 (Fig. 5C). The
majority (74%) of the sites observed in HB2 cells is consistent with
these conserved sites, indicating conservation between different
tissues. Consistent with our observations in HB2 cells, most NIPBL
binding sites in the LCL’s localize to the 59 ends of genes and are
enriched for the motifs of the transcription factors NF-Y and/or
SP1. Gene ontology analysis of the LCL NIPBL-bound genes
showed similar classes of genes as for HB2 cell, but no cell type-
specific functions such as immune response.
Although expected from patient-derived cell lines with NIPBL
haploinsufficiency, we did not observe significant differences in peak
number or peak intensity between controls and patient-derived
genomic regions as in (A). E Identical heatmaps generated for the RAD21 peaks observed in GM12878 cells. F Consensus motif derived de-novo from
NIPBL binding sites in HB2 cells. The region 650 bp around the peak maximum was used to determine motifs with MEME [33]. These motifs are
nearly identical to the respective motifs of the transcription factors NFYA and SP1, indicating that one or more transcription factors might colocalize
with NIPBL. G Binding of NFYB to NIPBL sites as discovered by the motif analysis in (D) and the comparison to binding sites of other transcription
factors in (E) was confirmed by ChIP-qPCR with anti-NFYB antibodies. H Heatmaps comparing +/2500 bp around NIPBL sites observed in LCL’s (N5)
with ChIP-sequencing data of various transcription factors (GM12878 cells) revealed a subset of transcription factors colocalizing with NIPBL. The
heatmaps reveal a strong correlation of PBX3, SP1, C-FOS, IRF3 and NFYA/B with NIPBL sites. I Heat maps showing the correlation of the factors in (H)
to NFYB sites at GpG island promoters (sites at CpG island promoters ranked according to strength with the strongest signals at the bottom). The
strongest correlation with the other factors is visible for the strongest NFYB peaks.
doi:10.1371/journal.pgen.1004153.g003
Figure 4. NIPBL is important to maintain gene activity. Transcript levels of genes with NIPBL-bound promoters and no cohesin sites close to
the gene (GLCCI1, BBX, TSPAN31, ARTS-1 and ZNF695) and the cohesin-regulated MYC gene were analyzed by RT-PCR/qPCR after RNAi depletion of
NIPBL, MAU2 or SMC3 in HB2 cells. The cells were synchronized in G2 phase and the transcript levels are normalized against the housekeeping gene
NAD. Transcripts of NIPBL, MAU2 and SMC3 were also analyzed to exclude that NIPBL affects transcription of MAU2 and SMC3 and vice versa. All three
genes serve also as negative control genes without NIPBL binding site at the promoter, although MAU2 and SMC3 have intronic cohesin binding
sites. P-values were determined using Students test using between 3 and 9 independent biological replicates. The p-value and number of replicates is
indicated for each graph. Values that are significantly different (P-value,0.05) from control RNAi are highlighted in red. (error bars 6 s.d.).
doi:10.1371/journal.pgen.1004153.g004
NIPBL as Novel Transcription Co-factor
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LCL’s. This is explained by the rather small differences of NIPBL
protein levels between CdLS patients and controls [22] due to
increased transcription from the intact allele. The ChIP-sequencing
method is not quantitative and therefore small changes of NIPBL
levels might not be reflected by peak intensity. To address this we
performed NIPBL ChIP-qPCR from four control cell lines and four
CdLS patient cell lines with primers for seven NIPBL binding sites
and one cohesin binding site (negative control). QPCR revealed a
reduction of the NIPBL signal between the control and patient-
derived cell lines (Fig. 5D; Suppl. Fig. S6), but also variations among
individual control- and patient-derived cell lines. In general, strong
NIPBL binding sites (OSBP, GPR108) seem to be more reduced than
weaker binding sites.
The position of NIPBL at promoters could be important for the
emergence of the developmental defects seen in CdLS cases.
Therefore we compared NIPBL binding sites with a list of genes
Figure 5. Position of NIPBL sites is conserved but the occupancy is reduced in CdLS. A NIPBL ChIP-sequencing data of a region of
chromosome 19 showing that NIPBL sites are conserved between CdLS patient cells and the control (M – Megabases). B CdLS patient and control cell
lines used in this study. The cell lines highlighted were used for ChIP-sequencing. The tables were derived from [18]. Nucleotide numbering refers to
the NIPBL B isoform cDNA sequence with GeneBank accession number NM_015384 and starting at the +1 position of the translation initiation codon.
C Venn diagrams indicating the number of NIPBL binding sites observed in the different LCL’s and also the sites consistently called in all three lines.
The majority of binding sites is conserved, although each cell line displays cell-line specific sites. D NIPBL binding is reduced in LCL’s derived from
CdLS patients. NIPBL ChIP was performed for four patient-derived cell lines and four age and gender-matched controls and qPCR analysis was
performed for seven NIPBL binding sites and one cohesin site. The enrichment compared to control IgG ChIP was calculated. The data for the
individual cell lines are displayed in Suppl. Fig. S6. Here we present the average relative enrichment for all control and patient-derived lines, p-values
derived with a Student test are indicated above the respective columns.
doi:10.1371/journal.pgen.1004153.g005
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found to be differentially expressed between LCL’s from CdLS
patients and controls [22]. We compared the list of 1501 unique
genes (FDR,0.05) found to be differentially expressed between
controls and CdLS patients [22] with our list of 1671 genes
neighbouring a NIPBL site (+/22 kb) in the patient-derived
LCL’s (PT1) and found that 155 (10%) of these genes are
differentially expressed (Table S7), a statistically significant
number when compared to a random list of genes (Fisher test,
p,0.001).
Discussion
In its best-studied function NIPBL promotes the initial
deposition of the cohesin complex onto chromatin, but is
dispensable for maintaining the subsequent association of cohesin
and chromatin. Rules that regulate the place and time of cohesin
loading and targeting to its various functions (sister chromatid
cohesion, transcriptional regulation, mediating long-range chro-
matin interactions and DNA damage repair) are only partly
understood. Factors interacting with chromatin-bound cohesin
such as the chromatin insulator CTCF [3,4,36] and to a smaller
extend estrogen receptor alpha (ERa) [37] determine the
localization of cohesin, but not its general chromatin binding
[3]. They might either direct NIPBL-dependent cohesin loading to
their binding sites or capture cohesin complexes that slide along
the DNA fibre.
First, we have addressed when cohesin, CTCF and NIPBL
associate with chromatin. So far, only very weak and probably
transient interactions have been reported between cohesin and
NIPBL in the non-chromatin-bound pool of nuclear proteins [38].
If these transient interactions are sufficient for NIPBL to bind
cohesin and recruit it onto chromatin, we would expect the
proteins to appear on chromatin at the same time after mitosis.
The same is true for CTCF. Analysis of cells exiting mitosis by
immunofluorescence staining showed that NIPBL, CTCF and
cohesin are largely excluded from metaphase chromosomes, as
seen before [3]. The signals of NIPBL and CTCF reappear on
DNA before the nuclear envelope reassembles; however, cohesin
overlaps with chromatin only during or after the nuclear envelope
reformation, reinforcing what was previously described by Gerlich
et al. [39]. NIPBL and CTCF are therefore already present when
cohesin starts to associate with chromatin. This is consistent with
cohesin being dispensable for CTCF localization [3]. NIPBL very
likely associates first with chromatin and then recruits’ cohesin
which is subsequently localized by CTCF to the co-occupied
binding sites.
Second, we determined the genomic localization of NIPBL by
ChIP using a NIPBL-specific antibody (NIPBL#1) form HB2 cells
enriched in G1 phase. We observed about 1100 highly enriched
NIPBL sites, mostly at active CpG-island promoters but also at
several LSU and SSU rRNA repeat regions. However, we do not
observe colocalization with cohesin or CTCF. Missing overlap
between NIPBL and cohesin was observed before. In yeast, non-
overlapping foci were observed for Scc2 (NIPBL ortholog in S.
cerevisiae) and Scc1 (RAD21 ortholog in S. cerevisiae) by immuno-
fluorescence microscopy on spread chromatin [40]. Further, a
ChIP-microarray study in budding and fission yeast observed a
transient overlap between cohesin and Scc2 in G1 phase cells and
a subsequent relocalization of cohesin to more permanent
positions between convergently transcribed genes [41]. Another
study in yeast confirmed this property of cohesin [42] while a third
study observed that colocalization of Scc2 with cohesin persists
also after cohesin loading [43]. In D. melanogaster the NIPBL
ortholog, Nipped-b, was found to colocalize with cohesin and
often overlap with RNA polymerase II, decorating entire active
transcriptional units [44]. Remarkably, cohesin does not colocalize
with CTCF in the fruit fly.
However, a study in mouse embryonic stem cells (mESC) used a
different NIPBL antibody (NIPBL#6) and reported that NIPBL
occupies enhancers and core promoter regions of transcriptionally
active genes which are also bound by cohesin and Mediator, a
huge transcriptional co-activator complex [13] (for review see
[45]).
Although we observe a similar localization of NIPBL, we did not
detect cohesin binding at NIPBL sites, even with relaxed
parameters for peak calling and using different ChIP protocols.
We have considered that the apparent discrepancies in the binding
patterns might arise due to the different ChIP protocols or
differences between pluripotent and differentiated cells, but have
disproved these hypotheses by ChIP-qPCR experiments using
both antibodies (Suppl. Fig. S5). Importantly, we do observe
significant differences between the performances of both antibod-
ies. Immunoprecipitation experiments showed that the NIPBL#1
antibodies recognize more bands originating from NIPBL than
NIPBL#6 antibodies (Suppl. Fig. S2). The NIPBL#1 antibodies
we use show a similar weak enrichment in ChIP-qPCR
experiments as observed for the NIPBL#6 antibodies in mESC
(Suppl. Fig. S5C). However, the NIPBL sites identified by our
study are highly enriched only by the NIPBL#1 antibodies, not by
NIPBL#6. We therefore conclude that the NIPBL#1 antibodies
very specifically recognize a number of ‘‘major’’ NIPBL binding
sites at active promoters where NIPBL localizes independently
from cohesin. The striking localization of NIPBL to promoter of
active genes suggested that NIPBL may have a direct role for the
transcription of the associated genes. We observe that the
transcript levels of several NIPBL-bound genes decrease after
RNAi depletion of NIPBL and MAU2. An effect on the transcripts
by impaired cohesin loading cannot be entirely excluded but we
observe that depletion of SMC3 does not have the same effect on
the transcripts. Therefore we hypothesize that NIPBL could have
a role as transcription factor, independent from its function for
cohesin. A differential effect of NIPBL and cohesin has already
been observed in the fly. Nipped-b facilitates activation of the cut
gene, but stromalin/Scc3, the fly orthologs of the SA1/SA2
cohesin subunit, inhibits its activation. A recent study in zebrafish
using morpholino knockdown observed a reduced transcription of
several genes, including the transcription factors sox17, foxa2 and
sox32, after NIPBL knockdown but not in smc3 and rad21
morphants [46].
We found that 11% of NIPBL-bound genes are transcription
factors according to Vaquerizas et al. 2009 [34]. A number of
them are very important during development and can also be
found on the list of genes differentially expressed in CdLS, for
example STAT3 and YBX1 (Table S7). Studies using mouse
models show that the absence of some of these factors (STAT3,
YBX1) leads to severe developmental defects and embryonic
lethality [47–49]. NIPBL deficiency could therefore interfere with
the proper timing and expression of transcription factors during
development.
The observation that NIPBL might be important for gene
expression lead us to ask whether NIPBL haploinsufficiency in
CdLS can be linked to transcriptional changes observed in these
patients. We have determined NIPBL sites in unsynchronized
LCL’s derived from CdLS patients with NIPBL haploinsufficiency
and normal controls. These binding sites are again mostly located
at CpG island promoters, not overlapping cohesin or CTCF. The
sites are in part conserved between different tissues, indicating that
there are constitutive and cell-type specific sites. The positions of
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the NIPBL binding sites are conserved between the LCL’s from
patients and controls, but the actual levels of NIPBL binding are
reduced in patients with a hypomorphic NIPBL truncation. To
link NIPBL sites to differential gene expression we compared
NIPBL-bound genes identified in a patient cell line (PT1) with
candidate CdLS target genes identified by Liu et al. [18] and
observed that a significant percentage (11%, Fischer test p,0.001)
of these genes have a NIPBL binding site. When we asked whether
NIPBL RNAi affects gene expression (Fig. 4) a subset of these
genes was tested and found to be sensitive for NIPBL knockdown.
This lead us to the conclusion that a part of the differentially
expressed genes in CdLS could be direct targets of NIPBL, and the
observed CdLS phenotype could be a cumulative effect of small
changes in the transcriptional program of a larger number of
genes.
Comparison of NIPBL sites in LCL’s with published binding
profiles of transcription factors in the lymphoblastoid cell line
GM12878 revealed that NIPBL colocalizes with several transcrip-
tion factors (SP1, NFY, PBX3, c-FOS, IRF3). Pbx3 belongs to the
Pbx family of TALE (three amino acid loop extension) class of
homeodomain transcription factors, which are implicated in
developmental and transcriptional gene regulation in numerous
cell types. Pbx3-deficient mice die after birth due to neuronal
malfunctions [50]. The factor is important for facial development
in mice [51] together with Pbx1 and Pbx2, and a human Pbx3
mutation was linked to heart defects [52]. IRF3 (interferon
regulatory factor 3) is an IRF family transcription factor which
translocates from the cytoplasm to the nucleus upon activation,
where it acts together with CBP/p300 to activate transcription of
interferons alpha and beta, as well as other interferon-induced
genes (for review see [53]). C-FOS is part of the AP-1 (activator
protein 1) transcription factor complex, which also contains the
JUN, ATF and MAF proteins. The complex regulates genes
involved in cell proliferation, differentiation, apoptosis, angiogen-
esis and tumour invasion and can have oncogenic but also anti-
oncogenic properties depending on cell type or differentiation state
[54]. How these factors functionally interact with NIPBL remains
to be investigated.
In summary, in this study we have addressed when and where
NIPBL binds to the human genome. We have discovered that a
subset of very strong ‘‘major’’ NIPBL binding sites preferentially
localizes to active promoters, together with a specific set of other
transcription factors. NIPBL is important for the activity of the
bound genes, suggesting that NIPBL influences transcription in
two ways; directly due to its binding to the promoters and
indirectly by loading of cohesin complexes which then regulate
genes by chromatin insulation and chromosomal long-range
interactions. The possibility that NIPBL directly affects expression
suggests that NIPBL-deficiency also directly contributes to the
complex CdLS phenotype by altering the transcriptional program
of developmentally important genes.
Materials and Methods
Antibodies
If different antibodies for the same protein were used the
antibodies were numbered to clearly identify them in the different
experiments.
NIPBL#1 - polyclonal rabbit anti-NIPBL antibody raised
against residues 2598–2825 of the X. laevis Scc2-1B, purified using
the epitope used for immunization (133M).
NIPBL#2 – polyclonal rabbit anti-NIPBL antibody raised
against residues 787–1164 of X. laevis Scc-1B, purified using
the epitope used for immunization (114M). Generation and
characterisation of the NIPBL #1 and NIPBL #2 antibodies have
been published already [38].
NIPPBL#3 – monoclonal rat anti-NIPBL, isoform A (long
isoform) NP_597677 (Absea, China, 010702F01 clone KT54)
NIPPBL#4 – monoclonal rat anti-NIPBL, isoform B (short
isoform) NP_056199 (Absea, China, 010516H10 clone KT55)
NIPPBL#5 - polyclonal rabbit anti-NIPBL antibody raised
against a region between amino acid residues 550 and 600 of
human NIPBL (Bethyl Laboratories A301-778A)
NIPPBL#6 - polyclonal rabbit anti-NIPBL antibody raised
against a region between amino acid residues 1025 and 1075 of
human NIPBL (Bethyl Laboratories A301-779A)
CTCF#1 –monoclonal mouse anti-CTCF (BD 612149)
CTCF#2 – polyclonal rabbit anti-CTCF antiserum (Millipore
07-729)
SA2 – monoclonal rat anti-SA2(STAG2) antibody (Frank
Sleutels and Niels Galjart)
SMC1A#1 - polyclonal rabbit anti-SMC3 antibodies (Bethyl
Laboratories A300-055A)
SMC3 – polyclonal rabbit anti-SMC3 antibodies obtained from
Jan-Michael Peters, described for immunoprecipitation and ChIP
in [55] and [3].
MAU2 – polyclonal rabbit anti-MAU2(Scc4), described in [38].
RNA Pol II – polyclonal rabbit antibody (N-20) (Santa Cruz sc-
899)
Tubulin – mouse anti-tubulin (Sigma)
Control IgG – rabbit whole serum
Rad21 – polyclonal rabbit anti-RAD21 (Jan-Michael Peters),
described in [29]
Cell culture
HeLa cells were cultured in DMEM supplemented with
0.2 mM L-glutamine, 100 units/ml penicillin, 100 mg/ml strep-
tomycin and 10% FCS.
HB2 cells (1-7HB2, a clonal derivative of the human mammary
luminal epithelial cell line MTSV1-7, [25]) were cultured in
DMEM supplemented with 0.2 mM L-glutamine, 100 units/ml
penicillin, 100 mg/ml streptomycin, 10% FCS, 5 mg/ml hydro-
xycortisone and 10 mg/ml human insulin.
Lymphoblastoid cell lines derived from controls and Cornelia de
Lange syndrome patients (Fig. 5B) were obtained from Ian Krantz
(The Children’s Hospital of Philadelphia, Philadelphia, Pennsyl-
vania, United States of America) and cultured in RPMI medium
supplemented with 0.2 mM L-glutamine, 100 units per ml
penicillin, 100 mg per ml streptomycin, 20% FCS.
SMC-LAP and Lamin-LAP Hela cells were were cultured in
DMEM supplemented with 0.2 mM L-glutamine, 100 units/ml
penicillin, 100 mg/ml streptomycin and 10% FCS and 0.2 mg/ml
G418.
RNAi depletion
The following siRNA oligos purchased form AMBION were
used to deplete the respective proteins for ChIP-analysis and
analysis of transcription
GL2
sense CGUACGCGGAAUACUUCGAtt
antisense UCGAAGUAUUCCGCGUACGtt
NIPBL
sense GCAUCGGUAUCAAGUCCCAtt
antisense UGGGACUUGAUACCGAUGCtt
MAU2
sense GCAUCGGUAUCAAGUCCCAtt
antisense UGGGACUUGAUACCGAUGCtt
SMC3
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sense AUCGAUAAAGAGGAAGUUUtt
antisense AAACUUCCUCUUUAUCGAUtg
The following hairpin siRNA constructs in the pLKO.1–puro
vector were obtained from the TRC Mission human library
(Sigma) and were used to deplete NIPBL demonstrate the
specificity of the NIPBL antibodies:
Control (clone SHC002) non-targeting sequence
NIPBL (clone TRCN0000129033) targeting sequence GCA-
GAGACAGAAGATGATGAA
The transfection of the siRNA oligos was performed with
Lipofectamine RNAiMAX (Invitrogen) according to the manu-
facturer’s instructions. The transfection of the hairpin siRNA
constructs was performed with Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Cells were harvested
48 hours after transfection.
Immunofluorescence staining
HeLa cells were grown on 18-mm cover slips and fixed with 4%
PFA. After permeabelization with TX100 and blocking with 3%
BSA the slides were stained with the respective antibodies.
Images were taken on a Leica DMRBE microscope equipped
with a Hamatsu CCD (C4880) camera with a 1006 objective.
Images were processed with Image J, the colouring; overlay of the
images was done with Adobe Photoshop.
Cell cycle analysis
Cells were fixed with methanol and after RNAse treatment the
DNA was stained with propidium iodine. The cells were analyzed
with a BD FACS Aria Cell sorter and FlowJo software.
Primers
See Table S6.
Immunoprecipitation
To prepare nuclear extracts from HeLa cells the cells were first
lysed by gentle resuspension in hypotonic buffer (20 mM Hepes-
KOH pH 8.0, 5 mM KCl, 1.5 mM MgCl2, 0.1 mM DTT).
Nuclei were collected by centrifugation and extracted for 30 min
on ice with extraction buffer (15 mM Tris-HCl pH 7.5, 1 mM
EDTA, 0.4 M NaCl, 10% sucrose, 0.01%TX-100, 1 mM DTT
and 1 tablet Complete (Roche) per 50 ml buffer). Debris were
removed by centrifugation (14000 rpm, 30 min).
The nuclear extract was diluted to 50% with IP buffer (20 mM
Tris-HCl pH 7.5, 100 mM NaCl, 5 mM MgCl2, 0.2% NP40,
1 mM NaF, 0.5 mM DTT) and incubated for 1 h at 4uC with the
respective antibodies. Affi-Prep Protein A support beads (BioRad)
were added and incubated 1 h at 4uC. The beads were washed 3
times with IP buffer and eluted by boiling with SDS-page loading
buffer. Western blots were analyzed with ECL+ reagent and
Alliance imaging system.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed as described
before [3]. In brief, cells at 70–80% confluence were crosslinked
with 1% formaldehyde for 10 min and quenched with 125 mM
glycine. After washing with PBS cells were resuspended in lysis
buffer (50 mM Tris-HCl pH 8.0, 1% SDS, 10 mM EDTA, 1 mM
PMSF and Complete protease inhibitor (Roche)) and chromatin
was sonicated (Diagenode Bioruptor) to around 500 bp DNA
fragments. Debris were removed by centrifugation, the lysate
diluted 1:4 with IP dilution buffer (20 mM Tris-HCl pH 8.0,
0.15 M NaCl, 2 mM EDTA, 1% TX-100, protease inhibitors)
and precleared with Affi-Prep Protein A support beads (BioRad).
The respective antibodies were incubated with the lysate for
14 h at 4uC, followed by 2 h incubation at 4uC with blocked
protein A Affiprep beads (Bio-Rad) (blocking solution: 0.1 mg/ml
BSA or 0.1 mg/ml fish skin gelatine). The beads were washed with
washing buffer I (20 mM Tris-HCl pH 8.0, 0.15 M NaCl, 2 mM
EDTA, 1% TX-100, 0.1% SDS, 1 mM PMSF), washing buffer II
(20 mM Tris-HCl pH 8.0, 0.5 M NaCl, 2 mM EDTA, 1% TX-
100, 0.1% SDS, 1 mM PMSF), washing buffer III (10 mM Tris-
HCl pH 8.0, 0.25 M LiCl, 1 mM EDTA, 0.5% NP-40, 0.5%
sodium desoxycholate) and TE-buffer (10 mM Tris-HCl pH 8.0,
1 mM EDTA). The beads were eluted twice (25 mM Tris-HCl
pH 7.5, 5 mM EDTA, 0.5% SDS) for 20 min at 65uC. The
eluates were treated with proteinase K and RNase for 1 h at 37uC
and decrosslinked 65uC over night. The samples were further
purified by phenol-chloroform extraction and ethanol-precipitat-
ed. The pellet was dissolved in 50 ml TE buffer.
This protocol was used to perform ChIP-qPCR or ChIP-
sequencing for CTCF, SMC3, NIPBL and RNA polymerase II.
For SMC1A a milder ChIP protocol from Duncan Odom’s group
was used [26].
For NIPBL ChIP sequencing HB2 cells were synchronized in
G1 phase by double thymidine block as described [8] (Suppl. Fig.
S3). All other preparations were done from unsynchronized cells.
For NIPBL ChIP after depletion of NIPBL or control by RNAi
the cells were synchronized in G1 phase by double thymidine
block, starting 6 hours after transfection of the siRNA oligos.
Details of the thymidine block to obtain HeLa cells in G1 phase
are described [3].
Samples were either submitted for genomic sequencing or
analyzed by qPCR using Platinium taq (Invitrogen) according to
the manufacturer’s instructions as described [3]. ChIP-qPCR
experiments at least three times and one representative example is
shown (SD was determined from qPCR replicates).
ChIP sequencing and peak detection
The ChIP DNA library was prepared according to the Illumina
protocol (www.illumina.com). Briefly, 10 ng of ChIPped DNA was
end-repaired, ligated to adapters, size selected on gel (200625 bp
range) and PCR amplified using Phusion polymerase as follow:
30 sec at 98uC, 18 cycles of (10 sec at 98uC, 30 sec at 65uC, 30 sec
at 72uC), 5 min at 72uC final extension. Cluster generation was
performed using the Illumina Cluster Reagents preparation. The
libraries for NIPBL, CTCF, SMC3, RNA PolII and the respective
controls generated from HB2 cells were sequenced on the Illumina
Genome Analyzer II, the SMC1A ChIP samples from HB2 cells,
the NIPBL ChIP samples from LCLs and the respective controls
were sequenced with the Illumina HiSeq2000 system. Read
lengths of 36 bases were obtained. Images were recorded and
analyzed by the Illumina Genome Analyzer Pipeline (GAP 1.6.0.
and 1.7.0.). The resulting sequences were mapped against
Human_UCSChg18 using the Bowtie [56] alignment software,
with the following parameters: bowtie -m 1 -S -k 1 –n 1. Unique
reads were selected for further analysis.
Peak calling for the ChIP sequencing data was performed with
SWEMBL (URL: http://www.ebi.ac.uk/,swilder/SWEMBL/)
as described [37] with the respective parameters described in
Table S1.
Co-localization read density profiles were done by extending a
region around each peak summit by +/2200 bp. Regions from
each data set were chosen in succession as viewpoints, and the
position of 59ends of the reads in corresponding regions in all data
sets was plotted. The profiles were ordered by the significance
score determined by the Swembl peak caller.
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Peak annotation. Complete Ensembl hg18 gene dataset was
downloaded on 13.04.2011. The genome was separated into 4
regions: promoter (+/21 kb from the TSS), upstream (25000
from the TSS), downstream (+5000 from the gene end) and gene
body. A region of +/2150 bp was extended around each peak
and overlapped with the genomic annotation.
Peaks were designated into one category based on the following
order of preference: promoterRgene bodyRupstreamRdown-
stream.
Repeat analyses
To investigate the repeat enrichment pattern, we used both
uniquely- and multiply-aligned reads. Multiply-aligned reads were
divided equally amongst all locations (N-times matched reads were
weighted as 1/N reads). The reads which were aligned to
reference genome more than 10 times were discarded. We applied
RPKM measure (reads per kilobase per million reads) which was
utilized for RNA-seq analyses [56], but we used ‘‘per 10 million
reads’’ instead of ‘‘per million reads’’. We counted the reads which
were aligned to each repeat class and normalized the counts
against the total number of aligned reads (whole-genome) and the
total length of each repeat class.
RNA sequencing
HB2 cells were enriched in G1 phase by double thymidine block
as described [8]. The RNA was isolated using TRI reagent (Sigma)
according to the supplier’s protocol. Two microgram of total RNA
was converted into a library of template molecules suitable for
sequencing according to the Illumina mRNA Sequencing sample
prep protocol. Briefly, polyA containing mRNA molecules were
purified using poly-T oligo attached magnetic beads. Following
purification, the mRNA is fragmented into ,200 bp fragments
using divalent cations under elevated temperature. The cleaved
RNA fragments are copied into first strand cDNA using reverse
transcriptase and random primers. This is followed by second
strand synthesis using DNA polymerase I and RNaseH treatment.
These cDNA fragments are end repaired, a single A base is added
and Illumina adaptors are ligated. The products are purified and
size selected on gel and enriched by PCR. The PCR products are
purified by Qiaquick PCR purification and used for cluster
generation according to the Illumina cluster generation protocols
(www.illumina.com). The sample was sequenced for 36 bp and
raw data was processed using Narwhal [57].
RNA sequencing analysis
RNA Seq reads were mapped to the Human UCSChg18
genome with Bowtie using the same parameters as for the ChIP
seq analysis. The coverage vector was calculated from unique
reads and the expression value was determined for each gene by
taking the RPKM [58] of the most highly expressed isoform (the
sum of coverage over exons was used as the numerator of the
equation). All genes with RPKM.0.6 were designated as
expressed.
Motif analysis
Motif analysis was performed with the tools MEME and
MEME-ChIP [33]. Residues +/250 bp of NIPBL binding site
peaks were retrieved and submitted to MEME-ChIP using
standard parameters.
To analyse whether the presence of the NFYA motif at NIPBL
sites is due to the presence of CpG islands or is a genuine property
of NIPBL binding we selected NIPBL binding sites close to only
one CpG island promoter (692 sites) and selected the same
number of CpG island promoters at random. The presence of the
NFYA motif was detected and the counts statistically analyzed
using a Fischer-test.
Identification of colocalizing transcription factors
We obtained from ENCODE [32] ChIP-sequencing data tracks
for transcription factors generated from GM12878 cells and
deposited by the Myers lab (HudsonAlpha Institute for Biotech-
nology) and the Snyder lab (Yale University). When called peaks
were available they were used, else replicates were pooled and
peak calling performed with MACS [58]. Peaks were sorted for
intensity and for the 10000, 5000 and 1000 (in case of NIPBL)
strongest peaks heatmaps were generated centred on NIPBL
binding sites conserved in the different lymphoblastoid cell lines
and also centred on the peaks of the respective transcription
factors. Overlapping patterns were selected by visual inspection of
the maps.
Myers lab (Haib). ATF2, ATF3, BATF, BCL1, BCL3,
BCLAF, BHLH, BRCA1, CFOS, CHD2, CTCF, EBF1, EGR1,
ELF1, ETS1, FOXM1, GABP, GCN5, IRF3, IRF4, JUND,
MAX, MEF2, MTA3, MXI1, NFATC1, NFE2, NFIC, NFYA,
NFYB, NRF1, NRSF, p300, PAX5, PBX3, PML, Pol2, Pol3,
POU2, PU.1, RAD21, RFX, RUNX3, RXLCH, RXRA, SIX5,
SMC3, SP1, SPT, SRF, STAT1, STAT3, STAT5, TBP, TCF1,
TCF3, TR4, USF1, USF2, WHIP, YY1, ZBTB3, ZEB1, ZNF143,
ZNF274, ZZZ3
Snyder lab (SYDH). BHLH, BRCA1, CFOS, CHD2,
CTCF, EBF1, GCN5, IRF3, JUND, MAX, MXI1, NFE2,
NFYA, NFYB, NRF1, p300, RAD21, RFX, SMC3, SPT,
STAT1, STAT3, TBP, TR4, USF2, WHIP, YY1, ZNF143,
ZNF274, ZZZ3
Transcript analysis
HB2 cells were transfected with the respective siRNA oligos using
Lipofectamine 2000 and were harvested after 48 hours. The RNA
was prepared using TRI reagent (Sigma). Remaining DNA was
removed by DNAse treatment and cDNA synthesis was performed
with Superscript reverse Transcriptase (Invitrogen) using oligo-dT
primers. The qPCR analysis was performed as described [3].
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of The Children’s Hospital of
Philadelphia. All patients provided written informed consent for
the collection of samples and subsequent analysis.
Supporting Information
Figure S1 Cohesin loading occurs after nuclear envelop
reformation. (A) To test and visualize the specificity of the
antibodies used for the immunostaining experiments HeLa cells
were treated with the respective siRNA for NIPBL, RAD21 and
CTCF and then seeded on cover slips in a mix with control
siRNA-treated cells to visualize the effect of the RNAi depletion
next to the control cells. The slides were stained with anti-NIPBL
#4, anti-RAD21 and anti-CTCF and for each secondary antibody
a control slide without primary antibody was included. The
undepleted cells are marked with white arrows in the antibody-
stained slides. (B, C) LaminA-LAP expressing HeLa cells (EGFP,
green) were stained with antibodies against (panel B) SA2/STAG2
(red) and (panel C) NIPBL (red). Images were taken from
interphase cells (I) and different stages during the exit from mitosis
(anaphase (A), late anaphase (LA), telophase (T) and early G1
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phase (EG1). In panel B the cohesin signal can only be observed
overlapping with chromatin when a nuclear envelop is visible
(white arrows in telophase and early G1 phase cells). In contrast
the NIPBL signal in panel C appears on chromatin already before
a nuclear envelop is visible (white arrows in late anaphase cells).
(PDF)
Figure S2 Characterization of NIPBL antibodies. We first
characterized different antibodies raised against NIPBL, a
320 kDa protein that is difficult to detect by immunoblotting
and immunofluorescense staining. For detection by western
blotting we used two rat monoclonal antibodies against the two
major isoforms of NIPBL, Isoform A (NP_597677, NIPBL#3) and
Isoform B (NP_056199, NIPBL#4). The isoforms are splice
variants of the last exon, residues 1–2683 are identical but isoform
A contains 121 and isoform B 14 unique C-terminal residues. (A)
Western blot showing that the band recognized by NIPBL#4 can
be depleted by NIPBL-specific siRNA in unsynchronized HeLa
cells while it remains well visible in two control siRNA
transfections. (B) Immunoprecipitations with the rabbit anti-
NIPBL antibodies NIPBL#1 and NIPBL#6 antibodies and
anti-SMC3 antibodies were performed from nuclear extract of
G1-phase enriched HeLa cells. Two identical western blots were
generated which were probed with rat monoclonal antibodies
against the two isoforms of NIPBL (NIPBL#3 for isoform A and
NIPBL#4 for isoform B) and one re-probed with anti-SMC1
(rabbit) after quenching of the rat antibody signal. Both isoform-
specific antibodies detected one major (.250 kDa) and minor
NIPBL bands in the G1-phase nuclear extracts (input lane).
Multiple bands for NIPBL could occur due to posttranslational
modifications of NIPBL. Significant difference between NIPBL#1
and #6 are visible in the immunoprecipitates. NIPBL#1, used by
us for ChIP-seq, immunoprecipitates all bands, while NIPBL#6,
used by Kagey et al. [13] for ChIP-seq from mouse ES cells,
precipitates only the lower bands. We concluded that the
NIPBL#1 antibody recognizes a wider spectrum of NIPBL
(posttranslationally modified) forms. Interestingly, the antibody
against the cohesin subunit (SMC3) did not precipitate any of the
NIPBL isoforms (Fig. 1C), consistent with previous observations of
very weak interactions between NIPBL and cohesin [38].
(PDF)
Figure S3 Determination of cell cycle stages by FACS analysis.
(A) HB2 cells growing logarithmically or enriched in G1 phase for
NIPBL ChIP were fixed with methanol, stained for the DNA
content with propidium iodine and analyzed by FACS. (B) HB2
cells treated with different siRNA’s were enriched in G2 phase.
Cells were fixed with methanol, stained for the DNA content with
propidium iodine and analyzed by FACS.
(PDF)
Figure S4 Specificity of the NIPBL antibody used for ChIP-
sequencing. (A) Genomic binding of NIPBL in a selected region on
chromosome 19 in comparison between HB2 cells and HeLa cells.
Both cell lines were enriched in G1 phase for the ChIP-sequencing
experiment. The position of the peaks is similar between HB2 and
HeLa cells, although the enrichment in HeLa was much weaker.
As controls the sequencing data from the respective input
materials are shown. (B) Western blot showing the depletion of
NIPBL in HeLa cells. Since MAU2 is also destabilized when
NIPBL is depleted it can be used as marker for NIPBL depletion
[38], which is rather difficult to blot. The band indicated with * is
an unspecific signal of the MAU2 antibodies and can be used as
loading control. (C) NIPBL and control ChIP was performed from
HeLa cells treated with NIPBL and control siRNA. QPCR
analysis with primers specific for several NIPBL binding sites
identified in HB2 cells shows that NIPBL RNAi dramatically
reduces the NIPBL ChIP signal. The experiment was performed
three times and one representative example is shown. (D) HeLa
cells were treated with control and NIPBL RNAi and stained with
different antibodies against NIPBL (green – NIPBL#1, rabbit
polyclonal; red - NIPBL#3, rat monoclonal) and with DAPI to
visualize DNA. Both antibodies show similar reduction of the
signal after NIPBL RNAi, indicating that both recognize the same
target protein. The images we selected to show also cells not
targeted by the siRNA to visualize the efficiency of the depletion.
(PDF)
Figure S5 Localization of NIPBL to repeats and comparison of
the NIPBL#1 and NIPBL#6 antibodies in mouse ES cells. (A)
ChIP/q-PCR validation of NIPBL-binding sites on repetitive
regions in HB2 cells. The experiment was performed in duplicate
and both samples are shown. Five primers for LSU repeats (LSU)
and three for SSU repeats (SSU) and one negative control region
(AMY) were analysed. (B, C) To compare both anti-NIPBL
antibodies we performed ChIP from mouse ES cells using the
protocol by Kagey et al. (upper panel) (B) and our protocol (C). We
tested several NIPBL sites at promoters that were identified by
Kagey et al. (Nanog, Lefty1, Oct4) and by our study (Tiam1, Ankhd1,
Sp1; initially identified in HB2 cells but found to be it conserved in
mouse ES cells). The left panel in (C) shows the full plot and the
right panel a zoom-in on the %IP of input values up to 0.05%IP of
input to visualize the ChIP performance at the ‘‘minor’’ low
affinity binding sites identified by Kagey et al.(mean n= 2, 6 s.d.).
(D) Immunostaining of mouse ES cells derived from Nipbl +/2
embryos for ES cell markers. (E) ChIP with NIPBL#1 (left panel)
and #6 antibodies (right panel) from control (IB10) and NIPBL +/
2 mouse ES cells (S. Goldberg, F. Grosveld unpublished data)
shows reduced Nipbl binding levels in Nipbl NIPBL +/2 cells
detected by both antibodies. (mean n= 2, 6 s.d.). (F) To compare
the ChIP efficiency of the NIPBL#6 antibodies with NIPBL#1 in
human cells we performed ChIP with NIPBL #6 from HB2 cells
(right panel) and compared it with the ChIP example also showed
in figure 2 E (left panel). (mean n= 2, 6 s.d.)
(PDF)
Figure S6 NIPBL-binding is reduced in LCL cells derived from
CdLS patients. NIPBL (NIPBL#1) and negative control ChIP
(IgG) was performed from lymphoblastoid cells derived from
CdLS patients and age-matched controls and analyzed by qPCR
with primers specific for seven NIPBL binding sites, one cohesin
binding site and a negative control site (AMY). The sites analysed
are indicated above the graph. The enrichment compared to the
control IgG ChIP was calculated. The experiment was performed
more than three times and a representative example is shown.
(PDF)
Table S1 Parameters used for peak calling with SWEMBL.
(PDF)
Table S2 Peaks identified with SWEMBL in the different
datasets.
(PDF)
Table S3 Position of the binding sites identified for the different
proteins relative to genes. Around each gene four regions were
considered to cluster the binding sites; upstream – 25000 to 2
1000 bp from the transcription start site (TSS); promoter – 21000
to +1000 bp from TSS; gene body – +1000 bp from TSS until the
end of the coding sequence; downstream – from the end of the
coding sequence to +5000 bp. Gene activity was scored based on
RPKM and genes with RPKM.0.6 were considered as expressed.
(PDF)
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Table S4 Classification of promoters and expression status of
genes bound by NIPBL, cohesin (SMC1A and SMC3), RNA Pol
II and CTCF. The region 21000 to + 1000 bp from TSS was
considered as promoter region.
(PDF)
Table S5 Functional annotation of genes with NIPBL binding
sites in HB2 cells by IPA analysis.
(PDF)
Table S6 Primers used for ChIP/qPCR and RT-PCR/qPCR.
(PDF)
Table S7 Genes with NIPBL binding sites in a patient-derived
lymphoblastoid cells (PT1) found to be differentially expressed in
CdLS patients with FDR,0.05 by Liu et al., 2009 (18).
(PDF)
Table S8 NIPBL ChIP signals in HB2 cells on different repeat
classes. RPKM measure (reads per kilobase per 10 million reads)
was calculated similar to the RNA-seq analyses (56) and an
enrichment compared to the input material (control) was calculated.
(PDF)
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